Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå.[1]
External links
References
- ↑ "Annual Report 2021/2022" (PDF). Diamyd Medical AB. Retrieved 20 February 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.